CA2798122A1 - Methods using lipoprotein-associated phospholipase a2 in an acute care setting - Google Patents

Methods using lipoprotein-associated phospholipase a2 in an acute care setting Download PDF

Info

Publication number
CA2798122A1
CA2798122A1 CA2798122A CA2798122A CA2798122A1 CA 2798122 A1 CA2798122 A1 CA 2798122A1 CA 2798122 A CA2798122 A CA 2798122A CA 2798122 A CA2798122 A CA 2798122A CA 2798122 A1 CA2798122 A1 CA 2798122A1
Authority
CA
Canada
Prior art keywords
subject
pla2
stroke
level
determined
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2798122A
Other languages
English (en)
French (fr)
Inventor
Joan Montaner
Maria Pilar Delgado Martinez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fundació Institut de Recerca Hospital Universitari Vall d'Hebron
Diadexus Inc
Original Assignee
Fundació Institut de Recerca Hospital Universitari Vall d'Hebron
Diadexus Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundació Institut de Recerca Hospital Universitari Vall d'Hebron, Diadexus Inc filed Critical Fundació Institut de Recerca Hospital Universitari Vall d'Hebron
Publication of CA2798122A1 publication Critical patent/CA2798122A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/02—Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
    • A61B5/02007—Evaluating blood vessel condition, e.g. elasticity, compliance
    • A61B5/02014—Determining aneurysm
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B8/00—Diagnosis using ultrasonic, sonic or infrasonic waves
    • A61B8/08—Clinical applications
    • A61B8/0891—Clinical applications for diagnosis of blood vessels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B8/00—Diagnosis using ultrasonic, sonic or infrasonic waves
    • A61B8/48—Diagnostic techniques
    • A61B8/488—Diagnostic techniques involving Doppler signals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • G01N2333/918—Carboxylic ester hydrolases (3.1.1)
    • G01N2333/92—Triglyceride splitting, e.g. by means of lipase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/321—Arterial hypertension
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Vascular Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Surgery (AREA)
  • Medical Informatics (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Wood Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
CA2798122A 2010-04-30 2011-05-02 Methods using lipoprotein-associated phospholipase a2 in an acute care setting Abandoned CA2798122A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33019310P 2010-04-30 2010-04-30
US61/330,193 2010-04-30
PCT/US2011/034728 WO2011137419A1 (en) 2010-04-30 2011-05-02 Methods using lipoprotein-associated phospholipase a2 in an acute care setting

Publications (1)

Publication Number Publication Date
CA2798122A1 true CA2798122A1 (en) 2011-11-03

Family

ID=44861949

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2798122A Abandoned CA2798122A1 (en) 2010-04-30 2011-05-02 Methods using lipoprotein-associated phospholipase a2 in an acute care setting

Country Status (6)

Country Link
US (1) US20130236450A1 (enExample)
EP (1) EP2563914A4 (enExample)
JP (1) JP2013527772A (enExample)
CN (1) CN103124785A (enExample)
CA (1) CA2798122A1 (enExample)
WO (1) WO2011137419A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7741020B2 (en) 2004-04-16 2010-06-22 Glaxo Group Limited Methods for detecting Lp-PLA2 activity and inhibition of Lp-PLA2 activity
US20150017671A1 (en) 2004-04-16 2015-01-15 Yaping Shou Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity
US20140283157A1 (en) 2013-03-15 2014-09-18 Diadexus, Inc. Lipoprotein-associated phospholipase a2 antibody compositions and methods of use
US20160349271A1 (en) * 2014-02-14 2016-12-01 Diadexus, Inc. Biomarkers for cardiovascular disease
KR101629560B1 (ko) * 2014-07-30 2016-06-13 경희대학교 산학협력단 부작용이 억제된 암치료용 약학 조성물
US10900063B2 (en) 2016-06-22 2021-01-26 Asahi Kasei Pharma Corporation Measurement of Lp-PLA2 activity

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6161547A (en) * 1999-01-15 2000-12-19 Coaxia, Inc. Medical device for flow augmentation in patients with occlusive cerebrovascular disease and methods of use
US20070077614A1 (en) * 2003-04-01 2007-04-05 Wolfert Robert L Uses of lp-pla2 in combination to assess coronary risk
AU2003902115A0 (en) * 2003-05-02 2003-05-22 The University Of Queensland Method of predicting functional outcome of a stroke using eeg measures
WO2005116268A2 (en) * 2004-05-27 2005-12-08 The Government Of The United States Of America As Represented By The Secretary, Department Of Health Differential expression of molecules associated with acute stroke
EP2166358A1 (en) * 2008-09-17 2010-03-24 Fundacio Institut de Recerca de l'Hospital Universitari Vall d'Hebron Differential diagnostic biomarkers of stroke mimicking conditions and methods of use thereof

Also Published As

Publication number Publication date
EP2563914A4 (en) 2013-11-20
US20130236450A1 (en) 2013-09-12
CN103124785A (zh) 2013-05-29
WO2011137419A1 (en) 2011-11-03
WO2011137419A8 (en) 2012-11-29
EP2563914A1 (en) 2013-03-06
JP2013527772A (ja) 2013-07-04

Similar Documents

Publication Publication Date Title
Ferrero et al. A retrospective study on early carotid endarterectomy within 48 hours after transient ischemic attack and stroke in evolution
Berger et al. Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y12 ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: the Early Rapid ReversAl of platelet thromboSis with intravenous Elinogrel before PCI to optimize reperfusion in acute Myocardial Infarction (ERASE MI) pilot trial
Meurin et al. Incidence, diagnostic methods, and evolution of left ventricular thrombus in patients with anterior myocardial infarction and low left ventricular ejection fraction: a prospective multicenter study
Hering et al. Renal nerve ablation reduces augmentation index in patients with resistant hypertension
Fassett et al. Effects of atorvastatin on arterial stiffness in chronic kidney disease: a randomised controlled trial
Page et al. Catheter ablation for atrial fibrillation on uninterrupted warfarin: can it be done without echo guidance?
Ikenaga et al. Longitudinal extent of lipid pool assessed by optical coherence tomography predicts microvascular no-reflow after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction
Finocchiaro et al. Latent obstruction and left atrial size are predictors of clinical deterioration leading to septal reduction in hypertrophic cardiomyopathy
JP2013527772A5 (enExample)
Airò et al. Disease-modifying effects of long-term cyclic iloprost therapy in systemic sclerosis. A retrospective analysis and comparison with a control group
Zhang et al. [Retracted] Controlled Decompression Alleviates Brain Injury via Attenuating Oxidative Damage and Neuroinflammation in Acute Intracranial Hypertension
Kurebayashi et al. Impact of the low-to high-density lipoprotein cholesterol ratio on composition of angiographically ambiguous left main coronary artery plaque
Johnson et al. Carotid artery intima-media thickness and the renin-angiotensin system
Mester et al. Magnitude of ST-segment elevation is associated with increased acute inflammatory response and myocardial scar in patients with acute myocardial infarction undergoing pPCI
Zuccalà et al. When stenting in renal artery stenosis? Update on pathophysiology of ischemic nephropathy and management strategies
Puato et al. Vascular remodelling in well-controlled hypertensive patients: the challenge of residual risk management
Ahmed Ebrahim et al. Predicting Post-Spinal Anesthesia Hypotension in Geriatric Patients: A Narrative Review of Ultrasonographic Carotid Flow Time and Inferior Vena Cava Collapsibility Index
Arnoldner et al. Tenth and twelfth nerve palsies in a patient with internal carotid artery dissection mistaken for cervical mass lesion
Awokola et al. PS 08-25 PREVALENCE AND PREDICTORS OF FALLS AMONG ELDERLY HYPERTENSIVES IN SOUTH-SOUTH NIGERIA
Adameová et al. The myocardial infarct size-limiting and antiarrhythmic effects of acyl-CoA: Cholesterol acyltransferase inhibitor VULM 1457 protect the hearts of diabetic–hypercholesterolaemic rats against ischaemia/reperfusion injury both in vitro and in vivo
Hesarur et al. Association between accessory nipple with coronary artery disease
Meda et al. Arterial ulcer
Zhao et al. PS 08-26 CORRELATION BETWEEN ORTHOSTATIC HYPOTENSION WITH CIRCDIAN RHYTHM, LEFT VENTRICULAR STRUCTURE AND FUNCTION IN AGED PATIENTS WITH HYPERTENSION
Lockwood et al. Transcatheter Aortic Valve Implantation in Patients with Low Gradient Aortic Stenosis and Preserved Left Ventricular Ejection Fraction
Rashid et al. The predictive value of tissue Doppler for left ventricular recovery and remodeling after primary percutaneous coronary intervention

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20170502